Is there a role for first generation TKIs in adjuvant setting of EGFR mutated early NSCLC?

Autor: Ospina AV; Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain., Provencio M; Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Publikováno v: Chinese clinical oncology [Chin Clin Oncol] 2023 Jun; Vol. 12 (3), pp. 30. Date of Electronic Publication: 2023 Jun 05.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs

Autor: Julie A. Vendrell, Jérôme Solassol, Isabelle Rouquette, Pierre Brousset, Etienne Coyaud, Romain Senal, Abdelali Bouidioua, Benoit Roch, Xavier Quantin, Sylvain Godreuil, Julien Mazieres, Jean-Louis Pujol

Publikováno v: Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2019, 25 (14), pp.4280-4289. ⟨10.1158/1078-0432.CCR-18-2683⟩

Purpose: The detection of preexisting EGFRT790M subclones and the assessment of their clinical significance in the pretreatment of patients with EGFRT790M non–small cell lung cancer (NSCLC) remain unclear. Experimental Design: A total of 179 tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca07306ab4218aa8d964f8ccdec1b6b
https://hal.umontpellier.fr/hal-02448987

Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery

Autor: Wenyan Ma, Ziyi Sheng, Yongliang Niu, Bo Yan, Yong Chen, Haitang Yang, Rong Li

Publikováno v: Heliyon, Vol 9, Iss 11, Pp e20955- (2023)

Introduction: Although third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) Osimertinib has been approved as adjuvant therapy for resected stage IIIA non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations

Externí odkaz: https://doaj.org/article/87d2d30c9f984c9c8ad007e4338e5c4d

Prolonged response to first‐generation tyrosine kinase inhibitor in a metastatic non‐small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review

Autor: Kien Hung Do, Duc Thanh Le, Tai Van Nguyen, Tu Anh Do, Chu Van Nguyen

Publikováno v: Respirology Case Reports, Vol 11, Iss 5, Pp n/a-n/a (2023)

Abstract A complex of G719X and S768I mutations is infrequently observed, constituting less than 0.3% of all EGFR‐positive non‐small cell lung cancer (NSCLC), and the response to first‐line TKIs is inconsistent in the literature. In this study,

Externí odkaz: https://doaj.org/article/55b592de4abc4787874ec8b7836ae75b